^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pembrolizumab subcutaneous (MK-3475 SC)

    i
    Other names: MK-3475 SC, MK 3475 SC, MK3475 SC
    Associations

    News

    Trials
    Company:
    Merck (MSD)
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    12ms
    KEYNOTE-603: Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=242, Recruiting, ModernaTX, Inc. | Active, not recruiting --> Recruiting | N=108 --> 242
    Enrollment open • Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)
    |
    EGFR mutation • ALK positive • ALK translocation • EGFR positive
    |
    Keytruda (pembrolizumab) • mRNA-4157 • pembrolizumab subcutaneous (MK-3475 SC)
    1year
    Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) (clinicaltrials.gov)
    P1, N=138, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    BRAF (B-raf proto-oncogene) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    BRAF mutation • BRAF V600
    |
    Keytruda (pembrolizumab) • pembrolizumab subcutaneous (MK-3475 SC)
    almost2years
    Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) (clinicaltrials.gov)
    P1, N=136, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2023 --> Dec 2023 | Trial primary completion date: Feb 2023 --> Dec 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    BRAF mutation • BRAF V600
    |
    Keytruda (pembrolizumab) • pembrolizumab subcutaneous (MK-3475 SC)
    2years
    KEYNOTE-A86: Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) (clinicaltrials.gov)
    P3, N=512, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • pembrolizumab subcutaneous (MK-3475 SC)